Literature DB >> 16517902

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

Munira Hussain1, Scott Fung, Evelien Libbrecht, Erwin Sablon, Carmela Cursaro, Pietro Andreone, Anna S F Lok.   

Abstract

The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16517902      PMCID： PMC1393162          DOI： 10.1128/JCM.44.3.1094-1097.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.

Authors:  Alfredo Marzano; Pietro Lampertico; Vincenzo Mazzaferro; Silvia Carenzi; Mauro Vigano; Raffaele Romito; Andrea Pulvirenti; Alessandro Franchello; Massimo Colombo; Mauro Salizzoni; Mario Rizzetto
Journal:  Liver Transpl       Date:  2005-05       Impact factor: 5.799

2.  Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.

Authors:  H L Chan; M Hussain; A S Lok
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

3.  Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.

Authors:  Chung Mau Lo; Chi Leung Liu; George K Lau; See Ching Chan; Irene O Ng; Sheung Tat Fan
Journal:  Liver Transpl       Date:  2005-07       Impact factor: 5.799

4.  Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

Authors:  M G Ghany; B Ayola; F G Villamil; R G Gish; S Rojter; J M Vierling; A S Lok
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

5.  Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Authors:  Anna S F Lok; Fabien Zoulim; Stephen Locarnini; Alessandra Mangia; Grazia Niro; Hilde Decraemer; Geert Maertens; Frank Hulstaert; Karen De Vreese; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

6.  Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Authors:  Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

7.  Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.

Authors:  Munira Hussain; Chi-Jen Chu; Erwin Sablon; Anna S F Lok
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
  7 in total
  19 in total

1.  Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids.

Authors:  Shuhei Hige; Yoichi Yamamoto; Shigeru Yoshida; Tomoe Kobayashi; Hiromasa Horimoto; Keiko Yamamoto; Takuya Sho; Mitsuteru Natsuizaka; Mitsuru Nakanishi; Makoto Chuma; Masahiro Asaka
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation.

Authors:  B Degertekin; Steven-Huy B Han; E B Keeffe; E R Schiff; V A Luketic; R S Brown; S Emre; C Soldevila-Pico; K R Reddy; M B Ishitani; T T Tran; T L Pruett; A S F Lok
Journal:  Am J Transplant       Date:  2010-03-23       Impact factor: 8.086

3.  Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.

Authors:  Hyunjung Jang; Jihyun Kim; Jae-jin Choi; Yeojin Son; Heekyung Park
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

4.  New developments in HBV molecular diagnostics and quantitative serology.

Authors:  D Scott Bowden; Alex J Thompson
Journal:  Hepatol Int       Date:  2008-02-13       Impact factor: 6.047

5.  Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.

Authors:  Bulent Baran; Ozlem Mutluay Soyer; Asli Cifcibasi Ormeci; Suut Gokturk; Sami Evirgen; Hamza Ugur Bozbey; Filiz Akyuz; Cetin Karaca; Kadir Demir; Fatih Besisik; Derya Onel; Mine Gulluoglu; Selim Badur; Sabahattin Kaymakoglu
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

6.  Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.

Authors:  Mariacarmela Solmone; Donatella Vincenti; Mattia Carlo Felice Prosperi; Alessandro Bruselles; Giuseppe Ippolito; Maria Rosaria Capobianchi
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Authors:  Evelien Libbrecht; Joke Doutreloigne; Hilde Van De Velde; Man-Fung Yuen; Ching-Lung Lai; Fred Shapiro; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

8.  Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Authors:  H G M Niesters; F Zoulim; C Pichoud; M Buti; F Shapiro; N D'Heuvaert; L Celis; J Doutreloigne; E Sablon
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

9.  Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list.

Authors:  Melissa K Osborn; Steven H Han; Arie Regev; Natalie H Bzowej; Michael B Ishitani; Tram T Tran; Anna S F Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10-31       Impact factor: 11.382

Review 10.  Hepatitis B virus variants.

Authors:  Watcharasak Chotiyaputta; Anna S F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.